Novel Tryptophan Hydroxylase Inhibitor TPT-001 Reverses PAH, Vascular Remodeling, and Proliferative-Proinflammatory Gene Expression

Overview

Journal JACC Basic Transl Sci

Date 2024 Aug 22

PMID 39170954

Authors

Ekaterina Legchenko

Philippe Chouvarine

Fatimunnisa Qadri

Edgar Specker

Marc Nazare

Radoslaw Wesolowski

Susann Matthes

Michael Bader

Georg Hansmann

Affiliations

Soon will be listed here.

Abstract

The serotonin pathway has long been proposed as a promising target for pulmonary arterial hypertension (PAH)-a progressive and uncurable disease. We developed a highly specific inhibitor of the serotonin synthesizing enzyme tryptophan hydroxylase 1 (TPH1), TPT-001 (TPHi). In this study, the authors sought to treat severe PAH in the Sugen/hypoxia (SuHx) rat model with the oral TPHi TPT-001. Male Sprague Dawley rats were divided into 3 groups: 1) ConNx, control animals; 2) SuHx, injected subcutaneously with SU5416 and exposed to chronic hypoxia for 3 weeks, followed by 6 weeks in room air; and 3) SuHx+TPHi, SuHx animals treated orally with TPHi for 5 weeks. Closed-chest right- and left heart catheterization and echocardiography were performed. Lungs were subject to histologic and mRNA sequencing analyses. Compared with SuHx-exposed rats, which developed severe PAH and right ventricular (RV) dysfunction, TPHi-treated SuHx rats had greatly lowered RV systolic (mean ± SEM: 41 ± 2.3 mm Hg vs 86 ± 6.5 mm Hg; < 0.001) and end-diastolic (mean ± SEM: 4 ± 0.7 mm Hg vs 14 ± 1.7 mm Hg; < 0.001) pressures, decreased RV hypertrophy and dilation (all not significantly different from control rats), and reversed pulmonary vascular remodeling. We identified perivascular infiltration of CD3 T cells and proinflammatory F4/80 and CD68 macrophages and proliferating cell nuclear antigen-positive alveolar epithelial cells all suppressed by TPHi treatment. Whole-lung mRNA sequencing in SuHx rats showed distinct gene expression patterns related to pulmonary arterial smooth muscle cell proliferation (Rpph1, Lgals3, Gata4), reactive oxygen species, inflammation (Tnfsrf17, iNOS), and vasodilation (Pde1b, Kng1), which reversed expression with TPHi treatment. Inhibition of TPH1 with a new class of drugs (here, TPT-001) has the potential to attenuate or even reverse severe PAH and associated RV dysfunction in vivo by blocking the serotonin pathway.

References

Zhang P, Sun Y, Peng R, Chen W, Fu X, Zhang L . Long non-coding RNA Rpph1 promotes inflammation and proliferation of mesangial cells in diabetic nephropathy via an interaction with Gal-3. Cell Death Dis. 2019; 10(7):526. PMC: 6614467. DOI: 10.1038/s41419-019-1765-0. View

Izikki M, Hanoun N, Marcos E, Savale L, Barlier-Mur A, Saurini F . Tryptophan hydroxylase 1 knockout and tryptophan hydroxylase 2 polymorphism: effects on hypoxic pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol. 2007; 293(4):L1045-52. DOI: 10.1152/ajplung.00082.2007. View

Aiello R, Bourassa P, Zhang Q, Dubins J, Goldberg D, De Lombaert S . Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension. J Pharmacol Exp Ther. 2016; 360(2):267-279. DOI: 10.1124/jpet.116.237933. View

Walther D, Bader M . A unique central tryptophan hydroxylase isoform. Biochem Pharmacol. 2003; 66(9):1673-80. DOI: 10.1016/s0006-2952(03)00556-2. View

Xue Q, Yan Y, Zhang R, Xiong H . Regulation of iNOS on Immune Cells and Its Role in Diseases. Int J Mol Sci. 2018; 19(12). PMC: 6320759. DOI: 10.3390/ijms19123805. View

Humbert M, Guignabert C, Bonnet S, Dorfmuller P, Klinger J, Nicolls M . Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2018; 53(1). PMC: 6351340. DOI: 10.1183/13993003.01887-2018. View

Walther D, Peter J, Bashammakh S, Hortnagl H, Voits M, Fink H . Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science. 2003; 299(5603):76. DOI: 10.1126/science.1078197. View

Ke R, Xie X, Li S, Pan Y, Wang J, Yan X . 5-HT induces PPAR γ reduction and proliferation of pulmonary artery smooth muscle cells via modulating GSK-3β/β-catenin pathway. Oncotarget. 2017; 8(42):72910-72920. PMC: 5641178. DOI: 10.18632/oncotarget.20582. View

Lazarus H, Denning J, Wring S, Palacios M, Hoffman S, Crizer K . A trial design to maximize knowledge of the effects of rodatristat ethyl in the treatment of pulmonary arterial hypertension (ELEVATE 2). Pulm Circ. 2022; 12(2):e12088. PMC: 9248796. DOI: 10.1002/pul2.12088. View

10.

Humbert M, Kovacs G, Hoeper M, Badagliacca R, Berger R, Brida M . 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022; 43(38):3618-3731. DOI: 10.1093/eurheartj/ehac237. View

11.

Li M, Sun X, Li Z, Liu Y . Inhibition of cGMP phosphodiesterase 5 suppresses serotonin signalling in pulmonary artery smooth muscles cells. Pharmacol Res. 2009; 59(5):312-8. DOI: 10.1016/j.phrs.2009.01.007. View

12.

Sitbon O, Channick R, Chin K, Frey A, Gaine S, Galie N . Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015; 373(26):2522-33. DOI: 10.1056/NEJMoa1503184. View

13.

Bader M . Inhibition of serotonin synthesis: A novel therapeutic paradigm. Pharmacol Ther. 2019; 205:107423. DOI: 10.1016/j.pharmthera.2019.107423. View

14.

Swinnen K, Quarck R, Godinas L, Belge C, Delcroix M . Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations. Eur Respir Rev. 2019; 28(154). PMC: 9488628. DOI: 10.1183/16000617.0050-2019. View

15.

Fulton D, Li X, Bordan Z, Wang Y, Mahboubi K, Rudic R . Galectin-3: A Harbinger of Reactive Oxygen Species, Fibrosis, and Inflammation in Pulmonary Arterial Hypertension. Antioxid Redox Signal. 2019; 31(14):1053-1069. PMC: 6767862. DOI: 10.1089/ars.2019.7753. View

16.

Suzuki Y, Day R, Tan C, Sandven T, Liang Q, Molkentin J . Activation of GATA-4 by serotonin in pulmonary artery smooth muscle cells. J Biol Chem. 2003; 278(19):17525-31. DOI: 10.1074/jbc.M210465200. View

17.

Abid S, Houssaini A, Chevarin C, Marcos E, Tissot C, Gary-Bobo G . Inhibition of gut- and lung-derived serotonin attenuates pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol. 2012; 303(6):L500-8. DOI: 10.1152/ajplung.00049.2012. View

18.

Specker E, Matthes S, Wesolowski R, Schutz A, Grohmann M, Alenina N . Structure-Based Design of Xanthine-Benzimidazole Derivatives as Novel and Potent Tryptophan Hydroxylase Inhibitors. J Med Chem. 2022; 65(16):11126-11149. DOI: 10.1021/acs.jmedchem.2c00598. View

19.

Xiao G, Wang T, Zhuang W, Ye C, Luo L, Wang H . RNA sequencing analysis of monocrotaline-induced PAH reveals dysregulated chemokine and neuroactive ligand receptor pathways. Aging (Albany NY). 2020; 12(6):4953-4969. PMC: 7138548. DOI: 10.18632/aging.102922. View

20.

West J, Carrier E, Bloodworth N, Schroer A, Chen P, Ryzhova L . Serotonin 2B Receptor Antagonism Prevents Heritable Pulmonary Arterial Hypertension. PLoS One. 2016; 11(2):e0148657. PMC: 4749293. DOI: 10.1371/journal.pone.0148657. View